At the Crossroads of Immunotherapy for Oncogene-Addicted Subsets of NSCLC

The authors discuss the effects of oncogenic driver mutations on the efficacy of immune-checkpoint inhibitors and the immune tumor microenvironment, as well as the potential vulnerabilities that could be exploited to overcome the challenges of immunotherapy for oncogene-addicted NSCLC.